aminopeptidas
n
ec
also
known
type
transmembran
metallopeptidas
superfamili
gluzincin
molecular
weight
approxim
kda
form
noncoval
bound
homodim
cellular
membran
conserv
pentapeptid
consensu
sequenc
hexxh
repres
motif
extracellular
metalloproteas
domain
therefor
belong
famili
aminopeptidas
enzym
hydrolyz
oligopeptid
preferenti
releas
neutral
amino
acid
end
small
peptid
first
describ
marker
hematopoiet
cell
myeloid
origin
express
mani
cell
tissu
includ
myeloid
fibroblast
brain
cell
hepatocyt
osteoclast
endometri
cell
epitheli
cell
liver
kidney
intestin
synapt
membran
central
nervou
system
broad
express
function
apn
strongli
depend
locat
intestin
brush
border
apn
involv
termin
degrad
small
peptid
scaveng
synapt
membran
apn
inactiv
endorphin
enkephalin
addit
apn
particip
inflammatori
reaction
process
peptid
apn
could
also
act
receptor
transmiss
gastroenter
viru
human
coronaviru
bestatin
leucin
obtain
cultur
filtrat
streptomyc
olivoreticuli
dipeptid
mw
bestatin
also
potent
competit
inhibitor
k
apn
antitumor
activ
immunomodul
activ
apn
inhibitor
includ
natur
inhibitor
bestatin
lapstatin
phebestin
curcumin
pasmmaplin
betulin
acid
figur
synthet
small
molecul
inhibitor
peptidomimet
nonpeptid
gener
speak
low
bioavail
rapid
elimin
proteolyt
labil
short
durat
action
etc
applic
peptid
clinic
limit
therefor
peptidomimet
peptid
mimic
becom
popular
research
aminopeptidas
n
play
crucial
role
tumor
progress
metastasi
cell
lung
cancer
human
pancreat
carcinoma
prostat
cancer
express
patient
associ
poor
prognosi
apn
express
suppos
involv
cancer
invas
metastasi
therefor
research
propos
apn
may
new
prognost
marker
cancer
progress
solid
tumor
format
new
blood
vessel
import
new
vasculatur
suppli
nutrient
oxygen
tumor
apn
also
particip
tumor
angiogenesi
regul
filopodia
format
endotheli
invas
meanwhil
apn
present
tumor
endotheli
cell
exist
blood
vessel
normal
tissu
proteolyt
degrad
extracellular
matrix
apn
proteas
matrix
metalloproteinas
contribut
growth
metastasi
tumor
studi
investig
bioactiv
apn
inhibitor
firstli
synthes
construct
quantit
relationship
model
direct
design
synthesi
novel
compound
laboratori
long
research
cours
design
synthesi
peptidomimet
compound
apn
inhibitor
peptidomimet
seri
newli
synthes
one
design
concept
combin
peptid
mimet
conform
restrict
furthermor
peptidomimet
share
common
feather
pharmacophor
bestatin
figur
apn
also
close
relat
angiogenesi
invas
tumor
cell
test
compound
realli
inhibit
tube
format
invas
cell
human
promyelocyt
leukemia
cell
human
immort
myelogen
leukemia
cell
human
alveolar
epitheli
cell
line
human
ovarian
clear
cell
adenocarcinoma
cell
line
human
hepatocarcinoma
cell
line
maintain
supplement
fetal
calf
serum
fc
human
glioblastoma
cell
line
grown
dulbecco
modifi
eagl
medium
supplement
fc
human
umbil
vein
endotheli
cell
huvec
maintain
endotheli
cell
medium
supplement
fetal
bovin
serum
ecg
penicillin
streptomycin
sciencel
research
laboratori
cat
cell
incub
humidifi
atmospher
contain
cell
incub
monoclon
antibodi
specif
bd
pharmingen
san
diego
ca
usa
clone
min
wash
twice
cell
resuspend
pb
analyz
facscan
facscalibur
san
jose
ca
usa
determin
enzym
activ
apn
determin
use
method
describ
previous
brief
cell
resuspend
pb
microtit
plate
differ
concentr
compound
ad
separ
incub
mm
sigma
st
loui
mo
usa
min
enzym
activ
estim
measur
absorb
nm
use
micropl
reader
model
hercul
ca
usa
plate
coat
basement
membran
matrix
matrigel
bd
bioscienc
bedford
usa
per
well
incub
h
huvec
pretreat
bestatin
day
plate
matrigel
supplement
inhibitor
h
photograph
taken
use
microscop
olympu
tokyo
japan
vitro
invas
assay
perform
use
invas
assay
describ
previous
matrigel
dilut
use
coat
invas
chamber
transwel
corn
pore
size
corn
costar
ny
usa
cell
treat
differ
compound
day
ad
upper
chamber
supplement
inhibitor
lower
compart
fill
fc
incub
h
matrigel
upper
side
filter
remov
cell
bottom
fix
methanol
stain
mgml
crystal
violet
dye
pictur
invad
cell
obtain
microscop
olympu
result
present
mean
number
invad
cell
five
differ
field
per
well
cell
per
well
cell
seed
plate
allow
grow
h
compound
ad
variou
concentr
two
day
treatment
cell
well
treat
mgml
mtt
reagent
incub
addit
h
cultur
remov
dimethylsulfoxid
ad
absorb
nm
measur
use
immunosorb
assay
reader
model
absorb
nm
use
refer
inhibit
rate
compound
calcul
odcontrol
od
mean
valu
three
replic
well
valu
determin
use
origin
softwar
originlab
corpor
northampton
usa
micha
constant
k
microsom
aminopeptidas
porcin
kidney
microsom
sigma
inhibit
constant
apn
inhibitor
determin
use
method
describ
previous
substrat
determin
k
aminopeptidas
incub
differ
concentr
substrat
assay
buffer
g
g
ml
ph
final
volum
reaction
veloc
measur
monitor
absorb
chang
nm
reaction
time
use
plate
reader
varioskan
thermo
electron
corpor
waltham
usa
equat
v
veloc
reaction
vm
maximum
veloc
reaction
concentr
substrat
use
analyz
k
aminopeptidas
determin
inhibit
constant
k
use
dixon
method
aminopeptidas
differ
concentr
inhibitor
incub
two
differ
concentr
substrat
respect
reaction
veloc
measur
monitor
absorb
chang
nm
reaction
time
equat
concentr
inhibitor
two
differ
concentr
point
intersect
versu
molecular
construct
geometri
optim
molecular
align
comfa
compar
molecular
field
analysi
model
gener
carri
use
tripo
sybyl
packag
dell
precis
workstat
compound
train
set
test
set
qsar
analys
peptidmimet
deriv
whose
valu
span
approxim
three
order
magnitud
compound
randomli
select
train
set
remain
seven
compound
use
test
set
number
sampl
test
set
approxim
train
set
biolog
data
obtain
convert
valu
use
depend
variabl
analys
tabl
molecul
construct
sybylsketch
modul
geometri
optim
use
powel
method
tripo
forc
field
converg
criterion
set
kcal
mol
assign
method
method
impli
molecular
align
procedur
molecul
share
scaffold
brief
molecular
forc
field
molecul
comput
use
sybylqsar
modul
first
steric
electrostat
field
extract
individu
extract
steric
electrostat
field
taken
templat
forc
field
molecul
align
templat
base
smallest
varianc
forc
field
align
set
molecul
shown
figur
compar
molecular
field
analysi
steric
electrostat
field
gener
use
columb
potenti
respect
carbon
probe
atom
charg
use
calcul
steric
field
electrostat
field
comfa
grid
space
use
model
partial
pl
regress
separ
perform
data
set
process
sampl
method
firstli
use
seek
optimum
number
compon
onc
comfa
model
comput
pl
obtain
onc
data
vitro
invas
assay
signific
differ
group
perform
student
bestatin
apn
inhibitor
modul
immun
respons
inhibit
growth
tumor
cell
therefor
apn
inhibitor
chemic
agent
inhibit
progress
solid
tumor
increas
cure
spectrum
apn
inhibitor
measur
fac
analysi
figur
show
express
aminopeptidas
n
variou
tumor
cell
line
cell
intens
express
lower
express
observ
tumor
cell
line
includ
made
us
interest
belong
leukemia
cell
line
howev
one
express
high
level
apn
express
low
level
apn
determin
whether
apn
inhibitor
influenc
viabil
tumor
cell
synthes
seri
small
molecular
apn
inhibitor
structur
compound
submiss
mtt
assay
use
screen
apn
inhibitor
higher
activ
toward
end
treat
cell
sensit
apn
inhibitor
express
high
level
aminopeptidas
n
differ
concentr
individu
compound
measur
absorb
compar
other
three
compound
greatli
inhibit
cell
viabil
therefor
chosen
investig
tabl
apn
enzym
activ
assay
indic
three
compound
bestatin
inhibit
enzym
activ
apn
figur
also
determin
whether
three
compound
could
inhibit
growth
solid
tumor
cell
line
result
show
less
inhibit
cell
viabil
cell
line
tabl
cytotox
activ
compound
question
focus
apn
inhibitor
mere
inhibit
growth
cell
apn
express
therefor
k
cell
line
express
low
level
apn
shown
figur
use
determin
cytotox
activ
compound
data
indic
three
compound
bestatin
inhibit
viabil
cell
figur
propos
bestatin
littl
cytotox
activ
multitarget
also
verifi
specif
test
compound
apn
trypan
blue
test
also
use
estim
cytotox
obviou
cytotox
effect
compound
cell
data
shown
gain
insight
inhibit
aminopeptidas
n
apn
inhibitor
kinet
studi
inhibit
carri
plot
construct
determin
k
shown
figur
mm
determin
k
valu
apn
inhibitor
dixon
method
employ
figur
k
valu
bestatin
data
correl
apn
enzym
activ
assay
figur
show
bestatin
potent
inhibitor
apn
show
lowest
affin
aminopeptidas
k
valu
also
correl
apn
enzym
activ
assay
howev
activ
compound
inhibit
viabil
cell
propos
also
target
protein
cytotox
activ
k
valu
capillari
morphogenesi
endotheli
cell
apn
activ
angiogenesi
signal
function
requir
progress
huvec
cell
model
use
determin
influenc
apn
inhibitor
endotheli
morphogenesi
verifi
whether
test
compound
could
suppress
format
structur
huvec
treat
differ
compound
cultur
basement
membran
matrix
matrigel
plate
h
incub
photograph
capillari
morphogenesi
acquir
compound
except
notabl
suppress
capillari
morphogenesi
figur
aminopeptidas
n
also
particip
invas
tumor
cell
therefor
activ
inhibit
tumor
cell
invas
compound
estim
firstli
confirm
whether
apn
activ
reduc
compound
data
indic
three
compound
bestatin
could
greatli
inhibit
activ
apn
express
surfac
cell
figur
invas
assay
use
matrigel
transwel
plate
perform
data
indic
compound
could
inhibit
invas
cell
figur
c
howev
bestatin
activ
compound
statist
result
comfa
pl
analys
present
tabl
ii
see
comfa
model
got
r
indic
qsar
model
robust
one
r
test
set
verifi
result
discuss
section
strictli
criterion
use
valid
comfa
model
observ
comfa
predict
valu
compound
support
inform
scatterplot
establish
base
figur
scatterplot
conclud
predict
close
observ
one
contour
map
comfa
electrostat
steric
model
repres
figur
comfa
steric
contour
map
green
contour
plot
figur
indic
region
bulki
group
relat
increas
bioactiv
yellow
contour
plot
figur
indic
region
bulki
group
favor
bioactiv
comfa
electrostat
contour
map
contour
figur
indic
region
presenc
neg
charg
increas
activ
contour
figur
show
region
posit
charg
group
favor
studi
undertaken
get
new
apn
inhibitor
screen
activ
seri
compound
three
compound
potent
research
accord
function
apn
activ
three
compound
estim
could
inhibit
activ
apn
affect
tube
format
invas
tumor
cell
determin
inhibit
constant
construct
model
research
relationship
anticanc
medicin
belong
cell
toxic
compound
inhibit
growth
cell
medicin
exert
anticanc
effect
also
affect
prolifer
normal
cell
therefor
avoid
side
effect
target
compound
aminopeptidas
n
involv
develop
cancer
ovarian
carcinoma
gastric
cancer
highli
express
tumor
cell
tumor
cell
still
express
low
level
aminopeptidas
n
apn
inhibitor
inhibit
progress
metastasi
tumor
cell
effect
apn
express
tumor
bring
littl
side
effect
although
aminopeptidas
n
still
express
tissu
compar
metastasi
cancer
littl
side
effect
accept
besid
direct
role
anticanc
apn
inhibitor
also
enhanc
apoptosi
cervic
cancer
meanwhil
apn
also
particip
diseas
lung
fibrosi
inflammatori
bowel
diseas
glomerulopathi
make
apn
good
therapeut
target
therapeut
target
protein
apn
compound
inhibit
growth
cell
mtt
assay
indic
compound
could
affect
viabil
tumor
cell
could
confirm
relationship
compound
apn
enzym
activ
assay
perform
one
interest
phenomenon
compound
could
effect
inhibit
viabil
tumor
cell
could
equal
affect
enzym
activ
apn
psammaplin
marin
natur
product
inhibit
aminopeptidas
n
may
cellular
target
therefor
hypothes
may
also
target
affect
viabil
tumor
cell
need
research
howev
could
greatli
inhibit
viabil
cell
express
high
level
apn
tabl
figur
markedli
affect
viabil
cell
line
express
low
level
apn
data
indic
test
compound
apn
hit
compound
aminopeptidas
n
play
import
role
angiogenesi
tumor
invas
import
metastasi
cancer
although
mechan
unclear
apn
crucial
mediat
angiogenesi
endotheli
cell
tube
format
invas
assay
perform
test
compound
could
markedli
inhibit
angiogenesi
invas
tumor
cell
know
capillari
vessel
format
tumor
tissu
provid
tumor
cell
opportun
get
vasculatur
system
get
circul
system
degrad
extra
cellular
matrix
requir
two
aspect
test
compound
affect
metastasi
primari
tumor
consid
inhibit
viabil
tumor
cell
test
compound
might
notabl
therapeut
effect
highli
metastat
cancer
contour
map
produc
envis
inform
content
deriv
comfa
model
comfa
steric
contour
map
green
contour
plot
figur
indic
region
bulki
group
relat
increas
bioactiv
yellow
contour
plot
figur
indic
region
bulki
group
favor
bioactiv
exampl
compound
trimethoxybenzamido
group
locat
region
isobutyl
group
compound
possess
ethyl
ester
group
region
might
caus
low
potenc
comfa
electrostat
contour
map
contour
figur
indic
region
presenc
neg
charg
increas
activ
contour
figur
show
region
posit
charg
group
favor
exampl
compound
amino
group
region
compound
got
good
potenc
might
caus
hydroxyl
group
region
base
observ
comfa
contour
map
use
inform
could
conclud
conduct
next
gener
compound
synthesi
take
exampl
optim
link
electroposit
substitu
group
benzen
ring
comfa
steric
contour
map
impli
larg
bind
pocket
around
region
comfa
electrostat
contour
suggest
region
may
electr
posit
favor
end
comfa
steric
contour
map
indic
hydroxim
acid
replac
smaller
group
thiol
group
evalu
predict
abil
comfa
model
train
set
molecul
test
set
seven
molecul
use
tabl
show
actual
compound
activ
data
predict
model
note
predict
activ
compound
close
actual
valu
figur
earli
studi
indic
high
valu
alon
insuffici
criterion
qsar
model
highli
predict
tropsha
cowork
introduc
new
set
valid
criteria
qsar
qspr
model
criteria
accept
appli
research
tropsha
hold
predict
qsar
model
satisfi
follow
condit
r
k
r
correl
coeffici
predict
observ
activ
test
set
r
quantiti
character
linear
regress
test
set
set
zero
differ
convent
r
best
fit
linear
regress
k
slope
regress
line
origin
qsar
model
establish
studi
match
tropsha
criterion
well
statist
data
shown
tabl
ii
conclus
activ
seri
apn
inhibitor
test
use
cell
model
three
potent
agent
chosen
pharmacolog
assay
could
inhibit
enzym
activ
apn
endotheli
angiogenesi
invas
tumor
cell
although
test
compound
less
activ
posit
medicin
bestatin
construct
model
direct
next
design
synthesi
work
near
futur
may
get
new
power
apn
inhibitor
